Viscosity, hemostasis and inflammation in atherosclerotic heart diseases

Gábor Késmárky, G. Fehér, Katalin Koltai, B. Horváth, K. Tóth

Research output: Article

32 Citations (Scopus)

Abstract

Background: In atherosclerotic diseases vascular reserve is impaired and pressure gradient is decreased, therefore the reduced blood fluidity can lead to tissue ischemia more rapidly. In previous investigations we demonstrated the deterioration of plasma and whole blood viscosities in patients with acute ischemic coronary syndromes, chronic coronary artery disease, and percutaneous transluminal coronary angioplasty. Methods: Hemorheological variables (plasma and whole blood viscosities, hematocrit, red blood cell aggregation), hemostaseological parameters (plasma fibrinogen and von Willebrand factor (vWf)), and platelet aggregation were detected in more recent studies in cardio- and cerebrovascular diseases, and diabetes mellitus. Common risk factors (lipid profile, smoking, glucose level, previous diseases) and medication were also recorded. Results: High portion of vascular patients were demonstrated to have poor ex vivo platelet inhibition. Effective antiplatelet treatment detected by aggregometry was related to lower plasma fibrinogen concentration and red blood cell aggregation and was also associated with less recurrent vascular events during the follow-up (p <0.001). Beside the impaired hemorheological characteristics, the diabetic patients showed elevated vWf activity, which turned to correlate with hemoglobin Alc concentration (p <0.01) rather than the fasting glucose. Summary: Our studies indicate the active role and interaction of hemorheological and hemostaseological factors in atherosclerotic heart diseases.

Original languageEnglish
Pages (from-to)67-73
Number of pages7
JournalClinical Hemorheology and Microcirculation
Volume35
Issue number1-2
Publication statusPublished - 2006

Fingerprint

Hemostasis
Viscosity
Heart Diseases
Inflammation
Cell Aggregation
Blood Viscosity
von Willebrand Factor
Fibrinogen
Blood Vessels
Erythrocytes
Cerebrovascular Disorders
Glucose
Coronary Balloon Angioplasty
Acute Coronary Syndrome
Vascular Diseases
Platelet Aggregation
Hematocrit
Coronary Artery Disease
Fasting
Diabetes Mellitus

ASJC Scopus subject areas

  • Hematology
  • Physiology

Cite this

Viscosity, hemostasis and inflammation in atherosclerotic heart diseases. / Késmárky, Gábor; Fehér, G.; Koltai, Katalin; Horváth, B.; Tóth, K.

In: Clinical Hemorheology and Microcirculation, Vol. 35, No. 1-2, 2006, p. 67-73.

Research output: Article

@article{df77f49119f6461d8a6b3ba6dca260ed,
title = "Viscosity, hemostasis and inflammation in atherosclerotic heart diseases",
abstract = "Background: In atherosclerotic diseases vascular reserve is impaired and pressure gradient is decreased, therefore the reduced blood fluidity can lead to tissue ischemia more rapidly. In previous investigations we demonstrated the deterioration of plasma and whole blood viscosities in patients with acute ischemic coronary syndromes, chronic coronary artery disease, and percutaneous transluminal coronary angioplasty. Methods: Hemorheological variables (plasma and whole blood viscosities, hematocrit, red blood cell aggregation), hemostaseological parameters (plasma fibrinogen and von Willebrand factor (vWf)), and platelet aggregation were detected in more recent studies in cardio- and cerebrovascular diseases, and diabetes mellitus. Common risk factors (lipid profile, smoking, glucose level, previous diseases) and medication were also recorded. Results: High portion of vascular patients were demonstrated to have poor ex vivo platelet inhibition. Effective antiplatelet treatment detected by aggregometry was related to lower plasma fibrinogen concentration and red blood cell aggregation and was also associated with less recurrent vascular events during the follow-up (p <0.001). Beside the impaired hemorheological characteristics, the diabetic patients showed elevated vWf activity, which turned to correlate with hemoglobin Alc concentration (p <0.01) rather than the fasting glucose. Summary: Our studies indicate the active role and interaction of hemorheological and hemostaseological factors in atherosclerotic heart diseases.",
keywords = "Hemostasis, Ischemic heart disease, Viscosity",
author = "G{\'a}bor K{\'e}sm{\'a}rky and G. Feh{\'e}r and Katalin Koltai and B. Horv{\'a}th and K. T{\'o}th",
year = "2006",
language = "English",
volume = "35",
pages = "67--73",
journal = "Clinical Hemorheology and Microcirculation",
issn = "1386-0291",
publisher = "IOS Press",
number = "1-2",

}

TY - JOUR

T1 - Viscosity, hemostasis and inflammation in atherosclerotic heart diseases

AU - Késmárky, Gábor

AU - Fehér, G.

AU - Koltai, Katalin

AU - Horváth, B.

AU - Tóth, K.

PY - 2006

Y1 - 2006

N2 - Background: In atherosclerotic diseases vascular reserve is impaired and pressure gradient is decreased, therefore the reduced blood fluidity can lead to tissue ischemia more rapidly. In previous investigations we demonstrated the deterioration of plasma and whole blood viscosities in patients with acute ischemic coronary syndromes, chronic coronary artery disease, and percutaneous transluminal coronary angioplasty. Methods: Hemorheological variables (plasma and whole blood viscosities, hematocrit, red blood cell aggregation), hemostaseological parameters (plasma fibrinogen and von Willebrand factor (vWf)), and platelet aggregation were detected in more recent studies in cardio- and cerebrovascular diseases, and diabetes mellitus. Common risk factors (lipid profile, smoking, glucose level, previous diseases) and medication were also recorded. Results: High portion of vascular patients were demonstrated to have poor ex vivo platelet inhibition. Effective antiplatelet treatment detected by aggregometry was related to lower plasma fibrinogen concentration and red blood cell aggregation and was also associated with less recurrent vascular events during the follow-up (p <0.001). Beside the impaired hemorheological characteristics, the diabetic patients showed elevated vWf activity, which turned to correlate with hemoglobin Alc concentration (p <0.01) rather than the fasting glucose. Summary: Our studies indicate the active role and interaction of hemorheological and hemostaseological factors in atherosclerotic heart diseases.

AB - Background: In atherosclerotic diseases vascular reserve is impaired and pressure gradient is decreased, therefore the reduced blood fluidity can lead to tissue ischemia more rapidly. In previous investigations we demonstrated the deterioration of plasma and whole blood viscosities in patients with acute ischemic coronary syndromes, chronic coronary artery disease, and percutaneous transluminal coronary angioplasty. Methods: Hemorheological variables (plasma and whole blood viscosities, hematocrit, red blood cell aggregation), hemostaseological parameters (plasma fibrinogen and von Willebrand factor (vWf)), and platelet aggregation were detected in more recent studies in cardio- and cerebrovascular diseases, and diabetes mellitus. Common risk factors (lipid profile, smoking, glucose level, previous diseases) and medication were also recorded. Results: High portion of vascular patients were demonstrated to have poor ex vivo platelet inhibition. Effective antiplatelet treatment detected by aggregometry was related to lower plasma fibrinogen concentration and red blood cell aggregation and was also associated with less recurrent vascular events during the follow-up (p <0.001). Beside the impaired hemorheological characteristics, the diabetic patients showed elevated vWf activity, which turned to correlate with hemoglobin Alc concentration (p <0.01) rather than the fasting glucose. Summary: Our studies indicate the active role and interaction of hemorheological and hemostaseological factors in atherosclerotic heart diseases.

KW - Hemostasis

KW - Ischemic heart disease

KW - Viscosity

UR - http://www.scopus.com/inward/record.url?scp=33746454200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746454200&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 67

EP - 73

JO - Clinical Hemorheology and Microcirculation

JF - Clinical Hemorheology and Microcirculation

SN - 1386-0291

IS - 1-2

ER -